Alexion Pharmaceuticals, Inc.
(NASDAQ : ALXN)

( )
ALXN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 3.28%61.090.0%$936.95m
AMGNAmgen, Inc. -1.21%253.151.3%$740.47m
NVAXNovavax, Inc. 31.62%104.56102.0%$729.34m
GILDGilead Sciences, Inc. -0.44%76.421.0%$691.31m
REGNRegeneron Pharmaceuticals, Inc. 2.17%640.882.5%$676.66m
BIIBBiogen, Inc. -0.54%268.351.6%$574.95m
VRTXVertex Pharmaceuticals, Inc. 2.66%299.061.9%$525.02m
ILMNIllumina, Inc. -1.92%372.123.5%$298.87m
ALXNAlexion Pharmaceuticals, Inc. -0.98%112.462.0%$233.18m
BMRNBioMarin Pharmaceutical, Inc. 0.21%127.984.3%$217.91m
SGENSeattle Genetics, Inc. 3.34%176.146.1%$205.38m
SRNESorrento Therapeutics, Inc. 3.00%7.381.8%$197.64m
IMMUImmunomedics, Inc. 1.30%41.1611.0%$181.04m
SRPTSarepta Therapeutics, Inc. 0.25%163.8913.9%$171.56m
INCYIncyte Corp. 0.80%108.652.5%$165.64m

Company Profile

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.